Attorney Docket No.: 10515.204-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu et al. Confirmation No: 7916

Serial No.: 10/586,026 Group Art Unit: 1652

Filed: July 13, 2006 Examiner: T. Saidha

For: Fungal Cell Wall Degrading Enzyme

TRANSMITTAL OF CORRECTED IDS SB08 FORM

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This application has been allowed. Applicants submitted an Information Disclosure Statement, an IDS SB08 form, and a copy of the references cited therein on July 13, 2006. The Office returned an initialed IDS SB08 form with the Notice of Allowance mailed on May 18, 2009. However, The Examiner did not initial two of the references because the references were not sufficiently identified.

Applicants therefore enclose herewith a corrected IDS SB08 form listing these two references, which is in accordance with the requirements of M.P.E.P. 609. Another copy of the references is enclosed for the Examiner's convenience.

It is respectfully requested that these references be considered by the USPTO, and that the Examiner return a copy of an initialed IDS SB08 form.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this submission or application.

Respectfully submitted,

Date: August 17, 2009 /Elias Lambiris, Reg. # 33728/

Elias J. Lambiris, Reg. No. 33,728 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110 (212) 840-0097